Spero Therapeutics (SPRO) Current Assets (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Current Assets data on file, last reported at $57.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 22.89% year-over-year to $57.6 million; the trailing twelve-month figure through Mar 2026 stood at $57.6 million (down 22.89% YoY), and the FY2025 full-year result was $67.3 million, down 37.28% from the prior year.
• Current Assets for Q1 2026 stood at $57.6 million, down from $67.3 million in the prior quarter.
• Across five years, Current Assets topped out at $140.2 million in Q1 2024 and bottomed at $52.0 million in Q2 2022.
• The 5-year median for Current Assets is $101.7 million (2023), against an average of $93.4 million.
• The widest annual swing landed in 2023, when Current Assets jumped 93.28%; it then tumbled 60.25% in 2025.
• A 5-year view of Current Assets shows it stood at $113.6 million in 2022, then advanced by 15.53% to $131.2 million in 2023, then slipped by 18.24% to $107.3 million in 2024, then slumped by 37.28% to $67.3 million in 2025, then retreated by 14.38% to $57.6 million in 2026.
• The last three Current Assets figures came in at $57.6 million (Q1 2026), $67.3 million (Q4 2025), and $52.3 million (Q3 2025), per Business Quant data.

Peer Comparison